Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Core Insights - Arvinas, Inc. is advancing its clinical programs with a focus on vepdegestrant, a PROTAC protein degrader targeting ER+/HER2- breast cancer, with significant milestones expected in 2025 [1][10][11] Clinical Trials and Data - A Phase 3 trial combining vepdegestrant with Pfizer's CDK4 inhibitor atirmociclib is set to begin in 2025, alongside a second-line Phase 3 trial with a CDK4/6 inhibitor [1][3] - Topline data from the Phase 3 VERITAC-2 trial of vepdegestrant monotherapy is anticipated in the first quarter of 2025 [1][5] - Initial data from the Phase 1 trial of ARV-102, a PROTAC LRRK2 degrader for Parkinson's disease, is expected in the first half of 2025 [2][4] Corporate Developments - Alex Santini has been appointed interim Chief Commercial Officer effective January 17, 2025, bringing over 30 years of experience in commercial organizations [7] - John Northcott, the outgoing Chief Commercial Officer, is leaving the company for personal reasons, also effective January 17, 2025 [8][9] Future Plans - The company plans to file an Investigational New Drug (IND) application for a novel PROTAC KRAS G12D degrader in 2025 [6] - Data disclosures are anticipated from multiple clinical and pre-clinical programs, including ARV-102 and ARV-393 [1][2]